Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging

Journal of Nuclear Medicine

Volumn 37, Issue 10, 1996, Pages 1589-1591

  Leslie, W D ^a,b   Abrams, D N ^a   Greenberg, C R ^a   Hobson, D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

dopamine; neuroimaging; neurotransmitter

Indexed keywords

DOPAMINE 2 RECEPTOR; EPIDEPRIDE; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; ARTICLE; BRAIN; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; ISOTOPE LABELING; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BENZAMIDES; BRAIN; BRAIN CHEMISTRY; CONTRAST MEDIA; DOPAMINE ANTAGONISTS; HUMANS; HUNTINGTON DISEASE; IODINE RADIOISOTOPES; MIDDLE AGED; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029822908     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
2. Brucke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220-228.
3. 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707.
4. Chiron C, Bulteau C, Loc'h C, et al. Dopaminergic D2 receptor SPECT imaging in Rett syndrome: increase of specific binding in striatum. J Nucl Med 1993;34:1717-1721.
5. Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 1993;34:1274-1281.
6. 18F]-N-methylspiroperidol and PET. J Nucl Med 1986;27:1878-1882.
7. Kessler RM, Ansari MS, Schmidt DE, et al. High affinity dopamine D2 receptor radioligands. 2. Iodine-125-epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991;49: 617-628.
8. Al-Tikriti MS, Baldwin RM, Zea-Ponce Y, et al. Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor. Nucl Med Biol 1994;21:179-188.
9. Kessler RM, Mason NS, Votaw JR, et al. Visualization of extrastriatal dopamine D2 receptors In the human brain. Eur J Pharmacol 1992;223:105-107.
10. Kung MP, Liu BL, Yang YY, Billings JJ, Kung HF. A kit formulation of iodine-123-IBZM: a new CNS D2 dopamine receptor imaging agent. J Nucl Med 1991;32:339-342.
11. Seibyl JP, Woods SW, Zoghbi SS, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with Iodine-123-IBZM. J Nucl Med 1992;33(11):1964-1971.
12. 123I]IBZM: a potential CNS D2 dopamine receptor imaging agent. J Nucl Med 1989;30:88-92.
13. Chabriat H, Levasseur M, Vidailhet M, et al. In vivo SPECT imaging of D2 receptor with iodine-iodolisuride. J Nucl Med 1992;33:1481-1485.
14. Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D2 receptor imaging agent. J Nucl Med 1990;31:648-654.
15. Hall H, Hogberg T, Halldin C, et al. NCQ 298, a new selective iodinated salicylamide ligand for the labeling of dopamine D2 receptors. Psychopharmacol 1991;103:6-18.
16. 123I-IBZM in humans. Ann Nuklearmedizin 1993;7:29-38.
17. 123I]IBZM [Abstract]. Eur J Nucl Med 1993;20:857.
18. Baron JC, Maziere B, Loc'H C, Sgouropolous P, Bonnet AM, Agid Y. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet 1985;1:1163-1164.
19. 125I]epidepride. Brain Res 1993;609: 237-243.
20. Kerwin RW, Pilowsky LS. Traditional receptor theory and its application to neuroreceptor measurements in funcitonal imaging. Eur J Nucl Med 1995;22:699-710.